Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Gentian Diagnostics ASA is a Norwegian medical diagnostics company founded in 2001 and headquartered in Moss, specializing in the development and manufacture of high-quality in vitro diagnostic (IVD) reagents using proprietary PETIA (particle-enhanced turbidimetric immunoassay) technology based on nanoparticle expertise. This innovation adapts clinically relevant biomarkers for efficient, high-throughput automated analyzers, improving laboratory productivity in detecting infections, inflammation, kidney failure, heart failure, and veterinary conditions. Its established portfolio includes Cystatin C for kidney function, fCAL turbo and GCAL for fecal calprotectin in inflammatory bowel disease, fPELA turbo, and Canine CRP, contributing to 26% annual revenue growth from 2019 to 2024. Products in development, such as NT-proBNP, target growth opportunities in a USD 1.8 billion serviceable market expanding at 5-10% annually. Gentian serves global human and veterinary diagnostics markets via sales offices in Sweden, the USA, and China, with a team of 63 employees led by CEO Njaal Kind, drawing expertise from leading IVD firms to drive scalable innovation. Since its 2016 IPO, the company plays a key role in enhancing diagnostic efficiency and cost savings in healthcare.
€3.44
+€0.15 (+4.56%)
EOD Jul 2, 2026
14.42% operating margin is respectable but not wide. ROIC at 6.09%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 16.1% YoY with margins expanding 4.1pp.
ROIC dropped from 8.64% to 6.09%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 176M
▲ +16.1% YoY
Net Income (TTM)
-NOK 15M
▼ -70.7% YoY
Op. Margin
-7.84%
▲ +4.1pp YoY
ROIC
6.09%
▼ -2.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
NOK 15M
▲ +1169.7% YoY
Op. Cash Flow (TTM)
NOK 20M
▲ +867.3% YoY
Net Debt
-NOK 83M
Net Cash Position
Cash & Equiv.
NOK 106M
3Y CAGR: +20.2%
Continue Research
Gentian Diagnostics ASA (GENT.XOSL) trades below a two-stage DCF intrinsic value of about NOK 32.17 per share, so at NOK 3.44 the stock looks undervalued (835.0% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Gentian Diagnostics ASA scores 67/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.0%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about NOK 32.17 per share for GENT.XOSL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around NOK 24.12. At today's NOK 3.44, that puts the stock about 835.0% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Gentian Diagnostics ASA scores 67 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a -7.8% operating margin and a 6.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Gentian Diagnostics ASA pays a regular dividend of about NOK 0.40 per share per year (typically in quarterly installments), a yield of roughly 1.0% at the current price. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For GENT.XOSL's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. GENT.XOSL currently trades below its estimated intrinsic value and scores 67/100 on quality (solid). It also yields about 1.0%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.